Purple Biotech 2025: The Legacy Assets Were Written Down, The Cash Buys Time For IM1240

Getting To Know The Company

Purple Biotech enters 2026 as a biotech that still looks, on paper, like a portfolio of four programs, but in practice is already behaving like a one-asset company. What is working now is the CAPTN-3 platform and the push to take IM1240 into the clinic. What no longer works the way it once did is the idea that CM24 and NT219 still give the story broad internal diversification. In 2025 both legacy clinical assets were written down to zero, and the company itself says their next development steps depend on partnering or dedicated outside funding.

A superficial reader can miss that point because the presentation still looks like a multi-asset biotech deck. IM1240 and IM1305 get clear front-page positioning, CM24 is still shown with Phase 2 efficacy signals, NT219 is still shown with active Phase 2 work, and the January 2026 toxicology release around IM1240 gives management a much stronger narrative than it had a year earlier. But this is still not a clean story. The value being created today is still mainly scientific and optional. It is not yet value that has become accessible to common shareholders.

That is also the real bottleneck. Purple Biotech's problem is not bank debt, a tight covenant, or a manufacturing site that suddenly needs heavy capital spending. In fact, as of year-end 2025 the company had no borrowings, lease liabilities of only $244 thousand, and no material tangible assets beyond leased office space. The active constraint is the financing bridge and the clinical proof bridge: can IM1240 enter the clinic on time, can CM24 and NT219 still turn into partnerships instead of remaining stranded in deck form, and can all of that happen before another deeply dilutive capital event takes over the story.

Four points need to be clear right away:

• The underlying burn did improve. Research and development expense fell 53% to $3.731 million, and adjusted operating loss fell to $6.667 million from $10.221 million.
• That improvement came together with a strategic retreat, not independently from it. The company wrote down CM24 and NT219 in-process R&D by a combined $20.482 million in 2025.
• The annual report only commits to at least 12 months of liquidity. The March presentation stretches the runway into the first half of 2027, but only through IM1240 toxicology, the IND filing, and Phase 1 initiation.
• This is not a stock under meaningful short pressure. Short interest as a percentage of float stands at just 0.02% versus a sector average of 0.38%. The real friction is micro-scale, dilution, and a capital structure loaded with warrants.

The quick economic map looks like this:

The company is now living between two different worlds. One is the world of a new platform finally approaching a real proof threshold. The other is the world of two older clinical assets that no longer carry accounting value and now need outside oxygen. This is no longer a biotech with several equivalent paths. It is a company asking the market to give IM1240 more time while the rest of the pipeline still has to prove it is not turning into archival optionality.

Events And Triggers

The CM24 And NT219 Write-Down Changed The Center Of Gravity

The biggest event in 2025 is not one isolated P&L line. It is the restructuring of the story itself. TyrNovo's IPR&D, which relates to NT219, fell from $6.172 million to zero. FameWave's IPR&D, which relates to CM24, fell from $14.310 million to zero. By year-end 2025 the only intangible asset left on the balance sheet is Immunorizon, meaning CAPTN-3, at $7.360 million.

That does not automatically mean CM24 and NT219 have no scientific value. It does mean that management and its valuation process no longer see a reasonable internally funded path under which Purple itself will generate cash flows from those programs sufficient to support balance sheet value. That is a major distinction. The balance sheet has already chosen a side.

The interesting contradiction is that the presentation still does not let those assets die. CM24 is still shown as a Phase 2 proof-of-concept program in PDAC with biomarker-enriched subsets, and NT219 is still shown as a clinical-stage program with active Phase 2 work and mechanism-based positioning. That is not a fake contradiction. It is the distinction between strategic option value and balance-sheet-carrying value. If a reader misses that distinction, they will either read the impairment as "zero" or the presentation as "everything is fine." Both readings are wrong.

IM1240 Is The Real Trigger, Not The Legacy-Asset Deck

On January 7, 2026 the company reported successful completion of a non-human primate toxicology study for IM1240, stating that it showed improved safety at doses up to 300-fold higher than a non-capped comparator, together with higher systemic exposure and a longer circulating half-life. The same release set a clear goal: regulatory submission in the second half of 2026 and continued progress toward first-in-human studies.

The March presentation makes the path more explicit: GLP tox completion in Q3 2026, IND submission in Q4 2026, and Phase 1 initiation in Q1 2027. That same deck says the company's runway extends into the first half of 2027 and covers those milestones. That matters because it defines exactly what the current cash is meant to buy: not meaningful clinical data, but entry into the clinic.

Management also says a pre-IND meeting with the FDA provided a clear roadmap for non-clinical and clinical development. That is constructive, but it is still not approval. This is where the gap between a strong scientific story and a real economic proof threshold sits. The right question today is not whether CAPTN-3 sounds differentiated. It is whether IM1240 actually crosses in 2026 and 2027 from preclinical promise into human testing.

CM24 And NT219 Are Still Alive, But Only On A Partnership Track

Future development of CM24 and NT219 is now explicitly conditioned on partnering or obtaining sufficient outside investment. That is a key line. It means the company is no longer presenting those programs as assets it intends to self-fund to the next stage.

At the same time, the presentation still works to preserve their strategic relevance. In CM24, management highlights the randomized PDAC study, a 19% reduction in risk of death, a 25% reduction in risk of progression or death, a 25% ORR, and biomarker-enriched subsets with hazard ratios of 0.22 and 0.39. In NT219, the company highlights combination data with cetuximab, an RP2D of 100 mg/kg, and a Phase 2 study in recurrent or metastatic head and neck cancer that was initiated in June 2025 with 58 planned patients.

The economic message is straightforward: the company is trying to preserve enough scientific life in those programs to support a transaction, but not enough internal financial commitment to keep pushing both itself. That does not eliminate value. It just moves that value from an internal engine to a deal option.

The Less Glamorous Trigger Is Nasdaq Compliance

On October 16, 2025 the company received a Nasdaq non-compliance notice after the ADS price stayed below the $1 minimum bid requirement for 30 consecutive trading days. On March 2, 2026 it changed the ADS ratio from 1:200 to 1:2000. On March 16, 2026 Nasdaq confirmed regained compliance.

This is a technical event, but it is a practical one. The company itself notes that if it falls out of compliance again within one year of this latest ADS ratio change, it would not be eligible for a further cure period. In other words, the March 2026 fix was not a permanent cushion. It was a technical time-buying move.

That changes the screen. Anyone who reads Purple only as a scientific option misses the fact that the stock also has to remain viable as a public-market instrument. At this scale, listing, dilution, and price mechanics are already part of the thesis, not a footnote.

Efficiency, Profitability And Competition

In a pre-revenue biotech, the right operating question is not gross margin or recurring revenue. It is whether the company is burning less cash without dismantling the only proof path that matters, and whether spending is moving away from carrying too many assets toward funding the right one.

The R&D Decline Is Real, But It Matters Who Paid For It

Research and development expense fell to $3.731 million in 2025 from $7.620 million in 2024. The mix matters more than the headline. Service-provider spend dropped to $2.569 million from $5.967 million. Salary and salary-related expense fell much less sharply, to $1.049 million from $1.536 million, and share-based payment in R&D barely moved, $113 thousand versus $117 thousand.

That means the savings came mainly from reduced outsourced clinical and development work, especially after the CM24 Phase 2 program was completed, rather than from a deep internal reset of the scientific core. That matters because it shows the cost structure was not "solved." The company mostly finished an expensive phase and narrowed the active front.

The Adjusted Loss Improved, But The Reported Loss Still Tells You Something Real

The company presents an adjusted operating loss of $6.667 million versus $10.221 million a year earlier. That is a better view of the underlying carrying cost after stripping out impairment and share-based accounting. On a narrow operating basis, the story did improve.

But that adjusted metric should not be allowed to erase what also happened in the same year. Reported operating loss rose to $27.458 million from $11.005 million, almost entirely because of the $20.482 million impairment of CM24 and NT219. That is not just accounting noise. The write-down reflects a changed view of asset value, development path, and self-funding capacity.

On the underlying burn line, the company became cheaper to carry. On the strategic line, it also became narrower.

The Real Competitive Test Is Not Against Another Biotech Deck, But Against The Proof Clock

Management presents CAPTN-3 as a tri-specific antibody platform that engages both T cells and NK cells, with a masking technology that is meant to improve safety and widen the therapeutic window. Those claims matter, and in the March materials they are supported with in vivo data, explants, and the recent toxicology results.

But analytically this is still a very early-stage competitive position. What will ultimately determine IM1240's value is not whether the slide set looks stronger than some other platform story. It is whether the company gets to IND, doses a first patient, and shows that the preclinical differentiation survives contact with real clinical development. Until then, the advantage is still potential, not a proven moat.

The same logic applies to CM24 and NT219. Yes, there are data points that can attract a partner. No, there is still no proof that Purple itself can take them to the next stage without paying for that with another layer of capital.

Cash Flow, Debt And Capital Structure

To read Purple Biotech correctly, the cash frame has to be explicit. Here the relevant frame is all-in cash flexibility, not normalized cash generation. This is not a business with a mature operating engine where the right question is maintenance versus growth spending. It is a company measuring how much time the current cash balance buys until the next proof point.

Cash Rose, But Only Because The Market Funded The Year

Cash and cash equivalents rose to $8.717 million in 2025 from $7.401 million. Including short-term deposits, the company held $9.574 million, of which $157 thousand was lease-guarantee cash. On the surface that looks stable. In reality, the year-end cash increase happened only because outside financing offset operating burn.

Operating cash flow was negative $5.656 million. Investing cash flow was positive $632 thousand. Financing cash flow was positive $6.333 million, mainly from the September 2025 public offering and ATM activity. Without capital markets, the year-end cash balance would have been lower.

That gap is the key point. Anyone looking only at the lower burn can conclude the problem is under control. Anyone looking at the full cash bridge sees that the company still needed market funding just to keep the cash line stable.

There Is No Debt Story, So The Pressure Flows Straight To Equity

As of year-end 2025 the company had no borrowings. Fixed obligations are also limited: lease liabilities of $244 thousand, lease repayments of $217 thousand during 2025, lease interest expense of $35 thousand, and no meaningful capital-expenditure commitments. That sounds positive, and in one sense it is, because there is no creditor or covenant layer that can break the story.

But that same point also sharpens the weakness. When there is no debt layer to absorb stress, every financing gap moves directly to common shareholders through offerings, ATM activity, ADS ratio changes, or warrant overhang.

The Capital Structure Is Heavier Than The Balance Sheet

At year-end 2024 the company had 259 thousand ADSs outstanding. By year-end 2025 that number had risen to 930 thousand. As of March 18, 2026 it also disclosed 1.273 million outstanding non-listed ADS warrants issued to investors, underwriters, and placement agents, plus 75,414 outstanding options and RSUs. In other words, the warrant layer alone is already larger than the ADS base that was outstanding at the end of 2025.

That is why value creation has to be separated from value access. Even if IM1240 clears a scientific milestone, the path by which that value reaches common shareholders still runs through a capital structure that has already absorbed heavy dilution and can absorb more.

The Report's Liquidity Commitment And The Deck's Runway Message Are Not The Same

Management says in the annual report that existing cash is sufficient for at least the next 12 months. That is a standard, conservative balance-sheet statement. The March presentation goes a step further and says runway extends into the first half of 2027 and covers IM1240 toxicology, IND filing, and Phase 1 initiation.

The gap between those two formulations is the heart of the cash thesis. There is no contradiction, but there is a clear boundary. The company is not saying that the current cash balance funds meaningful clinical data, a full Phase 1 program, or internally funded next-stage work for CM24 and NT219. It is saying the current cash buys the entry into the clinic. Once that is understood, 2026 reads correctly as a bridge year.

Outlook And What Comes Next

Purple Biotech is not entering 2026 as a breakout year. It is entering it as a bridge year with one main proof path and two secondary options.

Four points should dominate the forward read:

• IM1240 is the only asset the company is truly pushing forward on its own balance sheet.
• CM24 and NT219 remain relevant only if they attract a partner or targeted capital.
• The current cash position covers the route to Phase 1 initiation, not much beyond that.
• Any regulatory, clinical, or financing delay will hit a capital structure that is already stretched.

2026 Is A Bridge Year, Not A Breakout Year

The right phrase for the year ahead is "bridge year." Not a reset year, because something real is being built. Not a breakout year, because the company has still not crossed the threshold into human testing with IM1240. Capital markets are likely to focus on three checkpoints: GLP toxicology completion, IND filing during 2026, and Phase 1 initiation in early 2027.

At the same time, there are two side threads that can still move the story. The first is NT219, where the presentation points to interim data expected in 2026. The second is CM24, where the existing data package may still support partner discussions around biomarker-selected subsets. But those are still options, not the base-budget plan.

What The Market Is Really Likely To Measure

In the near term the market can react to a toxicology headline, a listing-compliance update, or an interim scientific readout. But over the next few quarters the test will be tougher:

• Does IM1240 move on the timeline management itself laid out.
• Does NT219 produce a signal that can support partner interest rather than only scientific interest.
• Did CM24 and NT219 leave the balance sheet only in accounting terms, or also in economic terms.
• And can the company get through those checkpoints without another capital event that dilutes shareholders faster than value is created.

That is also why the market can misread the 2025 filing on first glance. Anyone stopping at the $26.5 million net loss will miss that underlying burn actually improved. Anyone stopping at the presentation will miss that the balance sheet already gave up on two programs. Both messages have to be read together.

What Must Happen For The Read To Improve

The first thing that has to happen is operational proof on IM1240, not another layer of expanded narrative. GLP tox completion, IND filing, and Phase 1 initiation are the minimum milestones.

The second thing is a less aggressive financing mechanism. That does not have to mean a full-company partnership. Even a partial deal, a targeted investment, or some burden-sharing arrangement could materially improve the screen.

The third thing is discipline. If the company tries to re-activate too many programs in parallel without dedicated outside capital, the entire burn improvement of 2025 can disappear quickly.

Risks

The Scientific Risk Still Sits At The Core

IM1240 has still not been tested in humans. Every advantage presented today, including wider safety window, improved PK, and dual T-cell and NK-cell engagement, still rests on preclinical and toxicology work. That is a necessary base, but not a sufficient one.

The Financing Risk Has Moved From The Balance Sheet To The Stock

The company carries no debt, but it does carry a heavy dilution layer. It ended 2025 with 930 thousand ADSs outstanding, and by March 2026 it had disclosed 1.273 million ADS warrants. At the same time, the stock required an ADS ratio change to maintain Nasdaq compliance. Any failure on a near-term milestone can quickly become a question of where the next raise comes from and at what price.

The Operating Risk Comes From Leanness, Not Bloat

The company has only 10 employees, and only 4 of them are in research and development. That is a very lean operating structure. The advantage is cost control. The disadvantage is heavy dependence on CROs, outside manufacturers, and service providers. The annual report is explicit that the company relies mainly on third parties for CMC, preclinical studies, and clinical work. In a company this small, supplier delays translate directly into timeline risk.

The Legal Risk Is Not The Core Story, But It Is Large Relative To The Company's Scale

In November 2022 a claim of approximately NIS 9.2 million was filed against the company and other defendants. In January 2026 the mediation ended without success and a pre-trial hearing was scheduled for June 2026. The company says it cannot currently assess the probability of success or the potential exposure. At this scale, even a legal risk that is still unresolved is material enough to monitor.

The Short Base Is Almost Nonexistent, And That Is Information Too

Short interest as a percentage of float is only 0.02%, with an SIR of 0.14. That is very low, even against the sector average. The message is not that the market is confident. The message is that skepticism is not currently sitting in a crowded short position. It is sitting in the capital structure, the micro-scale equity value, and the difficulty of assigning full value to an asset that is still outside the clinic.

Conclusions

Purple Biotech exits 2025 as a biotech that is narrower and clearer, but also more fragile. What supports the thesis now is the IM1240 toxicology milestone, a lower underlying burn, and a cash balance that probably gets the company to its first clinical entry point. The main blocker is that the road beyond that point still depends on financing, partnerships, and a capital structure that has already been stretched. In the short to medium term the market will focus less on the write-down that already happened and more on whether 2026 actually brings the IND, partner interest, and a reasonable financing bridge.

The current thesis in one line: Purple Biotech is no longer a four-asset story. It is a focused wager that IM1240 reaches the clinic before the capital structure overwhelms the equation.

What changed relative to the older read of the company: CM24 and NT219 moved from potential internal growth engines to assets that now exist mainly as partnership options, while CAPTN-3 became the only asset that still sits at the center of both strategy and balance-sheet value.

The strongest counter-thesis: the market may be reading the write-down too harshly, while in practice the legacy assets can still produce a transaction and IM1240 may move into the clinic before another large financing becomes necessary.

What can change the market's reading over the short to medium term: GLP tox completion, IND filing during 2026, Phase 1 initiation in 2027, interim data in NT219, or, on the other side, any sign of another aggressive capital raise.

Why this matters: in Purple Biotech the gap between scientific value and value accessible to common shareholders is the whole story. Success will be judged not only by the quality of the data but also by the ability to reach that data without breaking the capital structure along the way.

What must happen over the next 2 to 4 quarters for the thesis to strengthen: IM1240 has to move on schedule, NT219 or CM24 need to generate tangible transaction-level interest, and the company has to get there without materially worsening the dilution profile. What would weaken the thesis is regulatory delay, no partner, or another financing round on terms that deepen dilution before real clinical proof arrives.

---